Using Physiologically Based Pharmacokinetic (PBPK) Modeling to Evaluate the Impact of Pharmaceutical Excipients on Oral Drug Absorption: Sensitivity Analyses

被引:27
|
作者
Chow, Edwin Chiu Yuen [1 ,2 ]
Talattof, Arjang [1 ,2 ]
Tsakalozou, Eleftheria [1 ,2 ]
Fan, Jianghong [1 ,2 ]
Zhao, Liang [1 ,2 ]
Zhang, Xinyuan [1 ,2 ]
机构
[1] US FDA, Div Quantitat Methods & Modeling, Off Res & Stand, Off Gener Drugs, Silver Spring, MD 20993 USA
[2] 10903 New Hampshire Ave,Bldg 75,Room 4690, Silver Spring, MD 20993 USA
来源
AAPS JOURNAL | 2016年 / 18卷 / 06期
关键词
Biopharmaceutics Classification System (BCS); excipients; gastrointestinal transporters; oral drug absorption; PBPK modeling; BIOPHARMACEUTICS CLASSIFICATION-SYSTEM; PEPTIDE TRANSPORTER PEPT1; COMMONLY USED EXCIPIENTS; P-GLYCOPROTEIN; CREMOPHOR EL; CACO-2; CELLS; BIOAVAILABILITY; PERMEABILITY; SURFACTANTS; METABOLISM;
D O I
10.1208/s12248-016-9964-4
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Drug solubility, effective permeability, and intestinal metabolism and transport are parameters that govern intestinal bioavailability and oral absorption. However, excipients may affect the systemic bioavailability of a drug by altering these parameters. Thus, parameter sensitivity analyses using physiologically based pharmacokinetic (PBPK) models were performed to examine the potential impact of excipients on oral drug absorption of different Biopharmaceutics Classification System (BCS) class drugs. The simulation results showed that changes in solubility had minimal impact on C-max and AUC(0-t) of investigated BCS class 1 and 3 drugs. Changes in passive permeability altered C-max more than AUC(0-t) for BCS class 1 drugs but were variable and drug-specific across different BCS class 2 and 3 drugs. Depending on the drug compounds for BCS class 1 and 2 drugs, changes in intestinal metabolic activity altered C-max and AUC(0-t). Reducing or increasing influx and efflux transporter activity might likely affect C-max and AUC(0-t) of BCS class 2 and 3 drugs, but the magnitude may be drug dependent. Changes in passive permeability and/or transporter activity for BCS class 2 and 3 drugs might also have a significant impact on fraction absorbed and systemic bioavailability while changes in intestinal metabolic activity may have an impact on gut and systemic bioavailability. Overall, we demonstrate that PBPK modeling can be used routinely to examine sensitivity of bioavailability based on physiochemical and physiological factors and subsequently assess whether biowaiver requirements need consideration of excipient effects for immediate release oral solid dosage forms.
引用
收藏
页码:1500 / 1511
页数:12
相关论文
共 50 条
  • [41] Prediction of the Impact of CYP2C19 Polymorphism on Drug-Drug Interaction between Voriconazole and Tacrolimus Using Physiologically- Based Pharmacokinetic Modelling
    Jin, Zhi-Ping
    Yan, Miao
    Li, Si-Ze
    Wang, Bao-Qing
    Xu, Qing
    Wu, Wei
    Li, Xiao-Yu
    Lv, Qian-Zhou
    Xiang, Xiao-Qiang
    BRAZILIAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2023, 59
  • [42] Predicting Nonlinear Pharmacokinetics of Omeprazole Enantiomers and Racemic Drug Using Physiologically Based Pharmacokinetic Modeling and Simulation: Application to Predict Drug/Genetic Interactions
    Wu, Fang
    Lu Gaohua
    Zhao, Ping
    Jamei, Masoud
    Huang, Shiew-Mei
    Bashaw, Edward D.
    Lee, Sue-Chih
    PHARMACEUTICAL RESEARCH, 2014, 31 (08) : 1919 - 1929
  • [43] Prediction of drug-drug interaction potential mediated by transporters between dasatinib and metformin, pravastatin, and rosuvastatin using physiologically based pharmacokinetic modeling
    Chang, Ming
    Bathena, Sai
    Christopher, Lisa J.
    Shen, Hong
    Roy, Amit
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2022, 89 (03) : 383 - 392
  • [44] Prediction of gastric pH-mediated drug exposure using physiologically-based pharmacokinetic modeling: A case study of itraconazole
    Yang, Eunsol
    Yu, Kyung-Sang
    Lee, SeungHwan
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2023, 12 (06): : 865 - 877
  • [45] Impact of differential particle size of fenofibrate nanosuspensions on biopharmaceutical performance using physiologically based absorption modeling in rats
    Jain, Divisha
    Thakur, Poonam Singh
    Thakore, Samarth D.
    Samal, Sanjaya K.
    Bansal, Arvind K.
    JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY, 2020, 60
  • [46] Global optimization of the Michaelis-Menten parameters using physiologically-based pharmacokinetic (PBPK) modeling and chloroform vapor uptake data in F344 rats
    Evans, Marina V.
    Eklund, Christopher R.
    Williams, David N.
    Sey, Yusupha M.
    Simmons, Jane Ellen
    INHALATION TOXICOLOGY, 2020, 32 (03) : 97 - 109
  • [47] Predicting human exposure of active drug after oral prodrug administration, using a joined in vitro/in silico-in vivo extrapolation and physiologically-based pharmacokinetic modeling approach
    Malmborg, Jonas
    Ploeger, Bart A.
    JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS, 2013, 67 (03) : 203 - 213
  • [48] Exploring the Impact of Developmental Clearance Saturation on Propylene Glycol Exposure in Adults and Term Neonates Using Physiologically Based Pharmacokinetic Modeling
    Olafuyi, Olusola
    Michelet, Robin
    Garle, Michael
    Allegaert, Karel
    JOURNAL OF CLINICAL PHARMACOLOGY, 2025, 65 (03) : 272 - 284
  • [49] Physiologically based pharmacokinetic modeling of altered tizanidine systemic exposure by CYP1A2 modulation: Impact of drug-drug interactions and cigarette consumption
    Jogiraju, Vamshi Krishna
    Heimbach, Tycho
    Toderika, Yuliana
    Taft, David R.
    DRUG METABOLISM AND PHARMACOKINETICS, 2021, 37
  • [50] Identification of solubility-limited absorption of oral anticancer drugs using PBPK modeling based on rat PK and its relevance to human
    Fink, Christina
    Lecomte, Marc
    Badolo, Lassina
    Wagner, Knut
    Maeder, Karsten
    Peters, Sheila-Annie
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2020, 152